Issued Patents All Time
Showing 1–25 of 30 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12285427 | Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor | Remi-Martin Laberge, Marco Demaria, Bennett G. Childs, Jan M.A. van Deursen, Nathaniel David +1 more | 2025-04-29 |
| 11980616 | Treating liver disease by selectively eliminating senescent cells | Remi-Martin Laberge, Marco Demaria, Nathaniel David, James L. Kirkland, Tamar Tchkonia +1 more | 2024-05-14 |
| 11963957 | Treating cardiovascular disease by selectively eliminating senescent cells | Remi-Martin Laberge, Albert Davalos, Marco Demaria, Nathaniel David, Jan M.A. van Deursen +2 more | 2024-04-23 |
| 11814680 | Biomarkers for detecting senescent cells | Johannes Grillari, Matthias Hackl, Abhijit KALE | 2023-11-14 |
| 11351167 | Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue | Remi-Martin Laberge, Marco Demaria, Nathaniel David, James L. Kirkland, Tamar Tchkonia +3 more | 2022-06-07 |
| 10655144 | Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cells | Marco Demaria, Francis Rodier, Remi-Martin Laberge | 2020-05-19 |
| 10478432 | Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Remi-Martin Laberge, Marco Demaria, Nathaniel David, Alain P. Vasserot, James L. Kirkland +5 more | 2019-11-19 |
| 10478433 | Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss | Remi-Martin Laberge, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland +5 more | 2019-11-19 |
| 10328058 | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques | Darren J. Baker, Marco Demaria, Albert Davalos, Bennett G. Childs, Jan M.A. van Deursen +5 more | 2019-06-25 |
| 10328073 | Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells | Remi-Martin Laberge, Marco Demaria, Nathaniel David, Alain P. Vasserot, James L. Kirkland +5 more | 2019-06-25 |
| 10279018 | Immunogenic compositions for inducing an immune response for elimination of senescent cells | Alain P. Vasserot, Serge Lichtsteiner | 2019-05-07 |
| 10258618 | Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen | Remi-Martin Laberge, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland +3 more | 2019-04-16 |
| 10213426 | Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population | Remi-Martin Laberge, Albert Davalos, Marco Demaria, Nathaniel David, Yi Zhu +2 more | 2019-02-26 |
| 10130628 | Treatment of joint pain | Nathaniel David, Albert Davalos, Remi-Martin Laberge, Marco Demaria, Alain P. Vasserot +6 more | 2018-11-20 |
| 10010546 | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Remi-Martin Laberge, Marco Demaria, Nathaniel David, Alain P. Vasserot, James L. Kirkland +5 more | 2018-07-03 |
| 9993472 | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 | Remi-Martin Laberge, Albert Davalos, Marco Demaria, Nathaniel David, Alain P. Vasserot +7 more | 2018-06-12 |
| 9980962 | Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease | Remi-Martin Laberge, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland +3 more | 2018-05-29 |
| 9901080 | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells | Marco Demaria, Remi-Martin Laberge, Francis Rodier, James B. Mitchell, Jan H. J. Hoeijmakers +1 more | 2018-02-27 |
| 9901081 | Transgenic mouse for determining the role of senescent cells in cancer | Marco Demaria, Francis Rodier, Remi-Martin Laberge, James B. Mitchell, Jan H. J. Hoeijmakers +1 more | 2018-02-27 |
| 9884065 | Inhibiting activity of senescent cells using a glucocorticoid | Remi-Martin Laberge, Francis Rodier, Marco Demaria | 2018-02-06 |
| 9855266 | Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline | Remi-Martin Laberge, Albert Davalos, Marco Demaria, Nathaniel David, Alain P. Vasserot +6 more | 2018-01-02 |
| 9849128 | Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells | Remi-Martin Laberge, Albert Davalos, Marco Demaria, Nathaniel David, Alain P. Vasserot +6 more | 2017-12-26 |
| 8846629 | Id-1 and Id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma | Pierre-Yves Desprez | 2014-09-30 |
| 8809291 | Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma | Pierre-Yves Desprez | 2014-08-19 |
| 8030012 | Id-1 and Id-2 genes and products as markers of epithelial cancer | Pierre-Yves Desprez | 2011-10-04 |